Hirosuke Yamaji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6108080/publications.pdf

Version: 2024-02-01

11	122	7	11
papers	citations	h-index	g-index
11	11	11	200
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Rates of atrial flutter occurrence and cavotricuspid isthmus reconduction after prophylactic isthmus ablation performed during atrial fibrillation ablation: a clinical study, review, and comparison with previous findings. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 67-76.	1.3	1
2	Potential of a Novel Chemical Compound Targeting Matrix Metalloprotease-13 for Early Osteoarthritis: An In Vitro Study. International Journal of Molecular Sciences, 2022, 23, 2681.	4.1	3
3	Efficacy of an Adjunctive Electrophysiological Test–Guided Left Atrial Posterior Wall Isolation in Persistent Atrial Fibrillation Without a Left Atrial Low-Voltage Area. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008191.	4.8	9
4	Correlation of the peak oxygen consumption and ventilatory aerobic threshold by cardiopulmonary exercise testing with atrial fibrillation recurrences after ablation in patients with paroxysmal atrial fibrillation. Journal of Arrhythmia, 2020, 36, 456-463.	1.2	1
5	Adjunctive left anterior line ablation induced left atrial dysfunction and dyssynchrony in atrial fibrillation ablation. Heart and Vessels, 2019, 34, 331-342.	1.2	9
6	Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology, 2019, 30, 2823-2833.	1.7	10
7	Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. Journal of Cardiovascular Electrophysiology, 2018, 29, 835-843.	1.7	9
8	Adjunctive interpulmonary isthmus ablation has no added effects on atrial fibrillation recurrence. Open Heart, 2017, 4, e000593.	2.3	3
9	Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2017, 69, 118-126.	1.9	8
10	Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Clinical Drug Investigation, 2016, 36, 837-848.	2.2	24
11	Usefulness of Dabigatran Etexilate as Periprocedural Anticoagulation Therapy for Atrial Fibrillation Ablation. Clinical Drug Investigation, 2013, 33, 409-418.	2.2	45